The Association for Clinical Oncology (ASCO) congratulates Dr. Francis Collins on his long and impactful tenure as Director of the National Institutes of Health (NIH).
Interventions that paired community-based health workers with low-income and minority patients with cancer improved quality of life and may be a more effective and sustainable way to ensure equitable cancer care, according to a study to be presented as part of the 2021 ASCO Quality Care Symposium.
Ten noteworthy studies from the 2021 Quality Care Symposium explore topics such as financial burden of cancer treatment, fertility preservation, hidden disparities in breast cancer, and more. Leading cancer experts are available to comment on the on-demand and scheduled broadcast content from the 2021 Quality Care Symposium.
The majority (72.3%) of oral anticancer drugs received by patients required prior authorization, which was found to be associated with delayed time to drug receipt, according to a study to be presented at the 2021 ASCO Quality Care Symposium.
The Association for Clinical Oncology (the Association) launched the ASCO Patient-Centered Cancer Care Certification, a new pilot that certifies outpatient oncology group practices and health systems that meet a single set of comprehensive, expert-backed standards for patient-centered care delivery. The pilot is based on recently published oncology medical home standards (OMH) from the American Society of Clinical Oncology (an affiliate of the Association) and the Community Oncology Alliance (COA).
Research covering cancer treatment delays due to insurance type, and improvements in cancer care and quality of life for low-income and minority patients seen with integrated community-based interventions will be highlighted in the 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium’s official Press Program. Studies featured in the Press Program are among the more than 300 abstracts that will be presented at the Symposium.
The Association for Clinical Oncology (ASCO) commends the Biden Administration for proposing to rescind the Most Favored Nation (MFN) model from consideration. ASCO has consistently opposed the ill-advised MFN model, as it would have had a devastating impact on people with cancer.
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today announced that 75 research sites applied and have been invited to participate in a pilot project testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity among clinical trial participants.
The American Society of Clinical Oncology (ASCO) and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards, which provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence-based cancer care.
Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) assert in a joint position statement released today.
A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation.
The addition of 1 year of the PARP inhibitor olaparib after completion of standard neoadjuvant or adjuvant chemotherapy, surgery and any radiation therapy needed, significantly improved invasive disease-free (IDFS) and distant disease-free survival (DDFS) in patients with BRCA1/2 germline mutations and high-risk early-stage breast cancer that is negative for human epidermal growth factor receptor 2-(HER2), according to new research to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Additional chemotherapy given after standard chemoradiation treatment does not improve survival for women with locally advanced cervical cancer, and is associated with additional side effects, according to results of a phase III international trial.
The addition of the immunotherapy agent toripalimab to standard first-line chemotherapy significantly delayed disease progression for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to new research. The phase III international study, to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, may represent a paradigm shift in the care of these patients, for whom there are currently few treatment options
Compared to standard of care chemotherapy, both a dual immunotherapy regimen and a single immunotherapy agent added to chemotherapy extends overall survival (OS) for patients with advanced esophageal squamous cell carcinoma (ESCC), particularly those positive for the immune checkpoint protein PD-L1, according to data from a phase III trial to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.